

# Composite grading algorithm for the National Cancer In Outcomes version of the Common Terminology Criteria

Clinical Trials

18, 104-114

DOI: [10.1177/1740774520975120](https://doi.org/10.1177/1740774520975120)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110063.	1.4	5
2	Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. <i>Dermatology and Therapy</i> , 2021, 11, 1319-1332.	1.4	23
4	Understanding Treatment Tolerability in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2150-2163.	0.8	33
5	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177 <sup>α</sup> -labeled Prostate-specific Membrane Antigen <sup>α</sup> -targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 80, 82-94.	0.9	53
6	Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 311-320.	0.6	5
7	SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e052494.	0.8	9
8	Transperitoneal versus extraperitoneal laparoscopic aortic lymph nodal staging for locally advanced cervical cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2256-2264.	0.5	7
9	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	0.8	72
10	Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 31, 34-41.	0.9	4
11	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 146-151.	0.9	12
12	Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors. <i>Archives of Medical Research</i> , 2022, 53, 113-121.	1.5	2
14	The Efficacy and Safety of Remimazolam Tosilate versus Etomidate-Propofol in Elderly Outpatients Undergoing Colonoscopy: A Prospective, Randomized, Single-Blind, Non-Inferiority Trial. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4675-4685.	2.0	33
15	Reconsidering tolerability of cancer treatments: opportunities to focus on the patient. <i>Supportive Care in Cancer</i> , 2022, 30, 3661-3663.	1.0	4
16	eSyM: An Electronic Health Record <sup>α</sup> -Integrated Patient-Reported Outcomes <sup>α</sup> -Based Cancer Symptom Management Program Used by Six Diverse Health Systems. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100137.	1.0	19
17	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0263402.	1.1	7
18	Strategies to Mitigate Chemotherapy and Radiation Toxicities That Affect Eating. <i>Nutrients</i> , 2021, 13, 4397.	1.7	9
20	LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. <i>Radiotherapy and Oncology</i> , 2022, 167, 317-322.	0.3	10
21	Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	0.7	3

#	ARTICLE	IF	CITATIONS
22	Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. <i>Immunotherapy</i> , 2022, 14, 521-530.	1.0	17
23	Persistent symptoms of fatigue, neuropathy and role of functioning impairment among indolent <scp>non-Hodgkin</scp> lymphoma survivors: A longitudinal <scp>PROFILES</scp> registry study. <i>British Journal of Haematology</i> , 2022, 197, 590-601.	1.2	6
24	Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. <i>BMJ</i> , The, 2021, 375, e066588.	3.0	16
25	Financial Hardship and Quality of Life Among Patients With Advanced Cancer Receiving Outpatient Palliative Care. <i>Cancer Nursing</i> , 2023, 46, 3-13.	0.7	2
26	High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial. <i>Cureus</i> , 2021, 13, e20353.	0.2	10
27	Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1). <i>Frontiers in Oncology</i> , 2021, 11, 769037.	1.3	1
28	Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic. <i>Value in Health</i> , 2022, 25, 931-936.	0.1	7
29	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , the, 2022, 9, e374-e384.	2.2	11
30	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	0.6	20
31	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. <i>Cancers</i> , 2022, 14, 2742.	1.7	6
32	A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring. <i>Current Oncology</i> , 2022, 29, 4370-4385.	0.9	14
33	Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. <i>Journal of Bone Oncology</i> , 2022, 35, 100441.	1.0	9
34	Conventional Laparoscopy versus Robotic-Assisted Aortic Lymph-Nodal Staging for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3332.	1.0	10
35	Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE. <i>British Journal of Cancer</i> , 2022, 127, 1629-1635.	2.9	3
36	Using the Pediatric Patient-reported Outcomes "common Terminology Criteria for Adverse Events to Longitudinally Measure Symptom Adverse Events of Children With Advanced Cancer. <i>Cancer Care Research Online</i> , 2022, 2, e020.	0.1	2
37	Remote Symptom Monitoring of Patients With Cancer Undergoing Radiation Therapy. <i>Cureus</i> , 2022, , .	0.2	0
38	The Discordance between Patient- and Clinician Reported Outcomes During (Chemo-)Radiation Therapy for Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
39	Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer. <i>Nutrients</i> , 2022, 14, 5183.	1.7	0

#	ARTICLE	IF	CITATIONS
40	Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure. <i>ESMO Open</i> , 2023, 8, 100775.	2.0	1
41	Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2). , 2023, 2, e0000178.		3
42	A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies. <i>Journal of the National Cancer Institute</i> , 2023, 115, 586-596.	3.0	1
43	A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis. <i>Quality of Life Research</i> , 2023, 32, 1807-1817.	1.5	3
44	Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e44105.	1.2	2
46	An Unsupervised Machine Learning Approach to Evaluating the Association of Symptom Clusters With Adverse Outcomes Among Older Adults With Advanced Cancer. <i>JAMA Network Open</i> , 2023, 6, e234198.	2.8	4
47	Methadone rotation versus other opioid rotation for refractory cancer induced bone pain: protocol of an exploratory randomised controlled open-label study. <i>BMC Palliative Care</i> , 2023, 22, .	0.8	1
48	Remote Activity Monitoring and Electronic Patient-Reported Outcomes Collection During Radiotherapy for Head and Neck Cancer: A Pilot Study. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	1.0	0
49	Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA). <i>BMJ Open</i> , 2023, 13, e063242.	0.8	2